Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Dec 10, 2010

Premium

Vermillion this week announced that its stockholders have voted to approve the reappointment of Gail Page, John Hamilton, and William Wallen as directors of the company.

Page, Vermillion's CEO, joined the company in January 2004 and has been a director since 2005. Hamilton has been on the company's board since April 2008. Prior to that he was vice president and chief financial officer of Depomed. Wallen was appointed to the board in February, before which he was a member of the company's scientific advisory board. Previously he was senior vice president and chief scientific officer at Idexx Laboratories.


Martin Madaus has joined the board of directors for array maker Quanterix.

Madaus recently was president, CEO, and chairman for Millipore, and before that he was president and CEO at Roche Diagnostics and vice president of business development for Roche Molecular Diagnostics. He currently is a director of the Massachusetts High Technology Council.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.